Deutsche Bank
FDMT icon

Deutsche Bank’s 4D Molecular Therapeutics FDMT Stock Holding History

Deutsche Bank’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$9.46M Buy
710,942
+2,898
+0.4% +$28.2K ﹤0.01% 1091
2026
Q1 		$6.59M Buy
708,044
+3,837
+0.5% +$33.4K ﹤0.01% 1187
2025
Q4 		$5.28M Buy
704,207
+160,876
+30% +$1.63M ﹤0.01% 1278
2025
Q3 		$4.72M Buy
543,331
+316,392
+139% +$1.89M ﹤0.01% 1336
2025
Q2 		$842K Sell
226,939
-9,218
-4% -$32.4K ﹤0.01% 2195
2025
Q1 		$763K Sell
236,157
-5,696
-2% -$26.8K ﹤0.01% 2290
2024
Q4 		$1.35M Sell
241,853
-560,784
-70% -$4.4M ﹤0.01% 2080
2024
Q3 		$8.68M Buy
802,637
+678,298
+546% +$11.3M ﹤0.01% 1059
2024
Q2 		$2.61M Buy
124,339
+2,479
+2% +$62.2K ﹤0.01% 1517
2024
Q1 		$3.88M Sell
121,860
-365,133
-75% -$9.32M ﹤0.01% 1367
2023
Q4 		$9.87M Buy
486,993
+471,424
+3,028% +$6.2M 0.01% 1004
2023
Q3 		$198K Sell
15,569
-660,584
-98% -$11M ﹤0.01% 2791
2023
Q2 		$12.2M Buy
676,153
+595,886
+742% +$11M 0.01% 915
2023
Q1 		$1.38M Buy
80,267
+5,298
+7% +$103K ﹤0.01% 1902
2022
Q4 		$1.67M Buy
74,969
+1,649
+2% +$25.5K ﹤0.01% 1757
2022
Q3 		$589K Buy
73,320
+60,027
+452% +$544K ﹤0.01% 2287
2022
Q2 		$93K Sell
13,293
-2,226
-14% -$21.6K ﹤0.01% 3554
2022
Q1 		$235K Sell
15,519
-1,764
-10% -$27.7K ﹤0.01% 3171
2021
Q4 		$379K Buy
17,283
+422
+3% +$10.3K ﹤0.01% 3006
2021
Q3 		$454K Buy
16,861
+6,220
+58% +$177K ﹤0.01% 3103
2021
Q2 		$257K Buy
10,641
+930
+10% +$28.5K ﹤0.01% 3640
2021
Q1 		$422K Buy
+9,711
New +$430K ﹤0.01% 3211

Other funds holding FDMT

JT
Jupiter Topco New York $245B AUM
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $630M AUM

Deutsche Bank's FDMT Position: Q2 2026 in Review

Deutsche Bank increased its 4D Molecular Therapeutics (FDMT) stake by 0.41% in Q2 2026, buying an estimated $28.2K and bringing the position to 710,942 shares worth $9.46M. The position accounts for ﹤0.01% of the portfolio, ranked #1091.

Deutsche Bank first reported a position in FDMT in Q1 2021 and has held it in 22 quarters since. The position peaked at $12.2M in Q2 2023. 158 funds tracked by Wall St. Rank hold FDMT as of Q2 2026.

  • Deutsche Bank held 710,942 shares of 4D Molecular Therapeutics worth $9.46M as of Q2 2026.
  • Deutsche Bank bought 2,898 4D Molecular Therapeutics shares in Q2 2026, an estimated $28.2K.
  • 4D Molecular Therapeutics made up ﹤0.01% of Deutsche Bank's portfolio in Q2 2026, its #1091 holding.
  • Deutsche Bank first reported a position in 4D Molecular Therapeutics in Q1 2021 and has held it in 22 quarters since.
  • Deutsche Bank's 4D Molecular Therapeutics position peaked at $12.2M in Q2 2023.
  • 158 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q2 2026.

Based on Deutsche Bank's 13F filing for Q2 2026, filed 7 Aug 2026.